Mild Cytokine Elevation, Moderate CD4 + T Cell Response and Abundant Antibody Production in Children with COVID-19
by Stacey
No Comments
Children with the disease in 2019 Coronavirus (COVID-19) reported mild symptoms and a better prognosis than their adult counterparts, but the difference in the immune response to SARS-CoV-2, among children and adults have not been reported.
Therefore we began this research to know the features of the immune response in children with COVID-19. Sera and whole blood cells from 19 children with COVID-19 during the different phases of the onset of illness was collected. The concentrations of cytokines, SARS-CoV-2 S-RBD or N-specific antibody and T cell immune responses were detected each. In children with COVID-19, only 3 out of 12 cytokines are elevated in acute serum, including interferon (IFN) -γ-induced protein 10 (IP10), interleukin ( IL ) -10 and IL – 16 .
Mild Cytokine Elevation, Moderate CD4 + T Cell Response and Abundant Antibody Production in Children with COVID-19
We observed an increase in T helper (Th) -2 cells and suppression in regulatory T cells (Treg) in patients during the acute phase, but did not get a significant response was found in necrosis factor-producing IFN-γ or tumor (TNF) – α-producing CD8 + T cells in patients. S-RBD and N IgM showed initial induction, while the S-RBD and N-induced IgG stand later in the healing phase. RBD potent S-IgA responses were observed but N IgA seemingly inconspicuous. Children with COVID-19 shown with immunophenotype less inflammatory than adults, including elevation of cytokines mediocre, while CD4 + T-cell response and activated CD8 + T-cell response, but they humoral immunity against SARS-CoV-2 is as strong as an adult. Our findings presented immunologic characteristics of children with COVID-19 and may provide some clues as to why children develop less severe disease than adults.
Treatment of cytokine storm in COVID-19 Patients with Immunomodulatory Therapy observational evidence indicates that excessive inflammation with a cytokine storm may play an important role in the development of acute respiratory distress syndrome (ARDS) in COVID-19. We report the emergency use immunomodulatory therapy utilizing extracorporeal selective device cytopheretic (SCD) in two patients with serum increased interleukin ( IL ) – 6 levels and flame retardant COVID-19 ARDS requiring extracorporeal membrane oxygenation (ECMO). Both patients were selected based on clinical criteria and increased levels of IL -6 (> 100 pg / mL) as a biomarker of inflammation.
Once identified, emergency / expand the use permit for the treatment of SCD is obtained and the patient agree. COVID-six of 19 patients (4 in the ECMO) with severe ARDS is also filtered by IL -6 levels less than 100 pg / mL and were not treated with SCD. Two patients enrolled ratio of PaO 2 / FiO 2 increased from 55 and 58-200 and 192 at 52 and 50 hours respectively. inflammatory index also decreased to IL -6 fall of 231 and 598 pg / mL of 3.32 and 1 16 pg / mL respectively. IL -6 / IL -10 ratio also declined from 11.8 and 18 to respectively 0.7 and 0.62.
Description: A competitive ELISA for quantitative measurement of Guinea pig Interleukin 16 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Interleukin 16 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: Quantitativesandwich ELISA kit for measuring Guinea Pig Interleukin 1 (IL-1) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Guinea Pig Interleukin 1(IL-1) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 4, IL-4 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 4, IL-4 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 5, IL-5 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 5, IL-5 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 2, IL-2 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig interleukin 2, IL-2 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig Interleukin 8, IL-8 in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Guinea pig Interleukin 8, IL-8 in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Both patients were successfully weaned off ECMO after 17 and 16 SCD treatment days each. The results observed with SCD therapy in critically ill COVID two 19 patients with severe ARDS and elevated IL -6 are encouraging. A multicenter clinical trial is ongoing with the FDA-approved Investigational Device Exemption to evaluate the therapeutic potential to effectively treat SCD-19 COVID ICU patients.
